Sign in
Taking people in United KingdomPhase 2

Early Natalizumab Treatment for First Signs of Multiple Sclerosis

Tests natalizumab shortly after first symptoms in adults with possible or confirmed multiple sclerosis.

Key facts

Who runs it
Queen Mary University of London
Where
London, United KingdomSee the 2 sites
Registry title
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
1 Dec 2022
Expected to end
31 Oct 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tyruko Injectable Product
  • Placebo
Record updated
7 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-55 who have just had a first episode suggesting multiple sclerosis (MS), or MS at first presentation, with at least two typical spots on a brain scan.

Age
18 to 55 years
Sex
All sexes can join.
Disease stage
Clinically isolated syndrome (CIS) or MS at first presentation, with two or more lesions on T2 weighted MRI suggestive of demyelination.
Earlier treatment
People cannot join if they take other disease modifying treatments for MS, or if they are on immunosuppressive therapy or were weakened by earlier therapy.
Biomarker or test result
Two or more lesions on T2 weighted MRI suggestive of demyelination.

Main reasons for not taking part

  • Allergy to Tyruko® or to its ingredients
  • Many chronic demyelinating lesions on MRI with no signs of recent activity
  • Higher risk of opportunistic infections, including a weakened immune system
  • Known active cancer, except cutaneous basal cell carcinoma
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Participant has provided informed consent
  • Age 18-55 years
  • Participant with CIS or MS at first presentation
  • Participants show two or more lesions on T2 weighted MRI suggestive of demyelination
  • Participant is willing and able to comply with clinical visits and procedures outlined in the study protocol

Who cannot take part

  • Participants with increased risk for opportunistic infections, including immunocompromised participants (those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies)
  • Combination with other Disease Modifying Treatments
  • Known active malignancies, except for participants with cutaneous basal cell carcinoma
  • Implants such as pacemaker, aneurysm clip in the brain and MRI-incompatible prosthetic heart valves
  • Significant comorbidities such as cardiac failure, renal failure, uncontrolled diabetes and uncontrolled hypercholesterolemia
  • History of stroke, thrombosis and/or myocardial infarction
  • Any other infection deemed, in the assessment of the PI or sub-investigator, clinically significant
  • Hypersensitivity to Tyruko® or to any of the following excipients:; Histidine; Histidine monohydrochloride; Sodium chloride; Polysorbate 80 (E433); Water for injections
  • Evidence of multiple chronic demyelinating lesions on MRI without signs of recent activity
  • Claustrophobia
  • Pregnancy or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United Kingdom

  • Royal London HospitalLondon, United KingdomContact: Klaus SchmiererNot yet recruiting
  • St. George's HospitalLondon, United KingdomContact: Liqun ZhangTaking people

About the trial

What the trial wants to find out

Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and the diagnosis of MS, and more than one year until Disease Modifying Treatment (DMT) begins.

Read full original descriptionShow less

Evidence suggests that shutting down inflammation using highly effective DMTs early after diagnosis leads to better long term clinical outcomes The AttackMS trial will test the effect of starting a highly-effective DMT licensed for MS, Tyruko® (Natalizumab 300mg), within a short time - 14 days - after symptom onset.

The 2 groups in the trial

  • Tyruko® 300mgExisting treatment, for comparison

    Tyruko® 300mg, administered via intravenous infusion in a 4 week cycle, for a total of 6 cycles

    Treatment: Tyruko Injectable Product

  • PlaceboPlacebo, for comparison

    Placebo, administered via intravenous infusion in a 4 week cycle, for 3 cycles, followed by Tyruko® 300mg, administered via intravenous infusion for a total of 3 cycles

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
AttackMS: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation
Plain-language title
Early Natalizumab Treatment for First Signs of Multiple SclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05418010, who can take part
Record updated
7 January 2026